000 | nab a22 7a 4500 | ||
---|---|---|---|
999 |
_c16802 _d16802 |
||
003 | PC16802 | ||
005 | 20220404121743.0 | ||
008 | 220404b xxu||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_9576 _aMorales Cerdán, José María _eNefrología |
||
100 |
_92597 _aMartinez-Flores, Jose A. _eInstituto de Investigación i+12 |
||
100 |
_92598 _aSerrano, Manuel _eInstituto de Investigación i+12 |
||
100 |
_92010 _aCastro Panete, María José _eInmunología |
||
100 |
_92596 _aAlfaro, Javier _eInstituto de Investigación i+12 |
||
100 |
_91504 _aGarcía Martín, Florencio _eNefrología |
||
100 |
_91220 _aMartínez González, Miguel Ángel _eAnatomía Patológica |
||
100 |
_91321 _aAndrés Belmonte, Amado _eNefrología |
||
100 |
_91487 _aGonzález Monte, Esther _eNefrología |
||
100 |
_91488 _aPraga Terente, Manuel _eNefrología |
||
100 |
_91510 _aPaz Artal, Estela _eInmunología |
||
100 |
_9661 _aSerrano Hernández, Antonio _eInmunología |
||
245 | 0 | 0 |
_aAssociation of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I. _h[artículo] |
260 |
_bJournal of the American Society of Nephrology : JASN, _c2015 |
||
300 | _a26(3):735-45. | ||
500 | _aFormato Vancouver: Morales JM, Martínez Flores JA, Serrano M, Castro MJ, Alfaro FJ, García F et al. Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I. J Am Soc Nephrol. 2015 Mar;26(3):735-45. | ||
501 | _aPMCID: PMC4341482 | ||
504 | _aContiene 56 referencias | ||
520 | _aIn the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti-β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. | ||
710 |
_9625 _aInstituto de Investigación imas12 |
||
710 |
_986 _aServicio de Nefrología |
||
710 |
_9395 _aServicio de Inmunología |
||
710 |
_9330 _aServicio de Anatomía Patológica |
||
856 |
_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341482/ _yAcceso libre |
||
942 |
_2ddc _cART _n0 |